Tanja Obradovic, Therapeutic Strategy Lead of Oncology at Novotech, Senior Advisor of Oncology Drug Development at HopeAI, shared a post on LinkedIn:
“ASCO conference is shaping into very impactful meeting this year with numerous reports announced. Highlighting Phase III trials that are raising interest and may bring highly improved treatment options.
ASCO 2026 – Phase III Reports Raising Interest That Can Change Treatment Landscape
This year American Society of Clinical Oncology (ASCO)meeting abstract/presentation titles have just been released with over 3000 updates coming. Among many, few key Phase III studies that are certain to raise interest based on initial reports of substantial patients benefit thus likely shaping future treatment landscape.
PROTEUS Phase III trial: evaluating apalutamide, a next-generation nonsteroidal antiandrogen that acts as a potent, direct androgen receptor (AR) inhibitor) plus androgen deprivation therapy (ADT) compared to placebo plus ADT in patients with high-risk, localized, or locally advanced prostate cancer preparing for radical prostatectomy (RP). Study treatment regimen includes 6-month neoadjuvant treatment, radical prostatectomy, followed by 6-month adjuvant treatment.
LIBRETTO-432 phase III trial: placebo-controlled study of adjuvant selpercatinib, a highly selective tyrosine kinase inhibitor that inhibits RET kinase, administered following definitive locoregional treatment in patients with stage IB-IIIA RET fusion-positive NSCLC that progressed following concurrent chemoradiation therapy.
Rasolute-302 Phase III trial: Evaluation of daraxonrasib, a RAS(ON) multi-selective RAS mutations inhibitor, compared to investigator’s choice of standard of care chemotherapy in patients with metastatic PDAC who were previously treated with one prior line of therapy with 5-fluorouracil based or gemcitabine-based regimen.
HARMONi-6 phase III trial: ivonescimab, an anti-PD-1 x VEGF bispecific, will be featured with results that compare ivonescimab + chemo versus tislelizumab + chemo for first-line advanced squamous NSCLC.
ASCO 2026 is certainly shaping into very impactful event this year with full abstract text coming on May 21st when community can take deeper look into full spectrum of data to be presented.”
Other articles featuring Tanja Obradovic on OncoDaily.